OPRD1 Protein, Human (Cell-Free, His)

The OPRD1 protein is a G protein-coupled receptor for enkephalins and opioids that undergoes ligand-induced conformational changes to activate signaling through G proteins and inhibit adenylate cyclase. Additionally, it reduces neurotransmitter release by affecting ionic currents. OPRD1 Protein, Human (Cell-Free, His) is the recombinant human-derived OPRD1 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of OPRD1 Protein, Human (Cell-Free, His) is 372 a.a., with molecular weight of 41.9 kDa.

The OPRD1 Protein, a G-protein coupled receptor, serves as a receptor for endogenous enkephalins and a subset of other opioids. Upon ligand binding, the receptor undergoes a conformational change, initiating signaling via guanine nucleotide-binding proteins (G proteins) and modulating downstream effectors like adenylate cyclase, resulting in the inhibition of adenylate cyclase activity. Additionally, OPRD1 inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Crucially, it plays a pivotal role in the perception of pain and opiate-mediated analgesia, contributing to the development of analgesic tolerance to morphine. OPRD1 may form homooligomers and forms a heterodimer with OPRM1, interacting with GPRASP1 and RTP4 to regulate cell surface localization of the OPRD1-OPRM1 heterodimer. These interactions highlight the complex regulatory mechanisms through which OPRD1 modulates opioid signaling and analgesic responses.

Human

E. coli Cell-free

N-10*His

P41143 (M1-A372)

4985

MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAIAITALYSAVCAVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELLCKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVGVPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRLRSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAALHLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTACTPSDGPGGGAAA

Monomer: 39 kDa Dimer: 78 kDa

Greater than 90% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.22 μm filtered solution PBS, 0.05% Brij-78, 6%Trehalose, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add 5-50% of glycerol (final concentration). Our default final concentration of glycerol is 50%. Customers could use it as reference.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.